Katharina Dürr

Katharina Dürr has extensive experience in the field of biochemistry and structural biology. Katharina began their career in 2003 as a research scholar in the group of Prof. Dr. Simone Fulda at the University of Ulm's University Children's Hospital, studying the molecular causes of apoptosis resistance in pancreatic cancer. In the same year, they also completed their Master's thesis in Biochemistry at Goethe-Universität Frankfurt a. Main. In 2004, they began their Ph.D. studies in Biophysical Chemistry at the Max Planck Institute of Biophysics, where they worked with Dr. as their supervisor. In 2006, they continued their Ph.D. studies at TU Berlin's Max-Volmer-Laboratory for Biophysical Chemistry with Prof. as their supervisor. In 2010, they were a Postdoctoral Researcher at Oregon Health and Science University. In 2016, they became the Group Leader at the Structural Genomics Consortium (SGC). Most recently, in 2020, they were appointed as the Director of Structural Biology and Protein Biochemistry at OMass Therapeutics.

Katharina Dürr's education history includes a Bachelor's Degree in Biochemistry from Goethe University (1998-2000), a Master's Degree in Biochemistry from Goethe University (2000-2003), and a Doctor of Philosophy (Ph.D.) in Biophysical Chemistry from Technische Universität Berlin (2006-2010). Katharina also attended the University of Oxford, though no degree was obtained.